1. ACOG practice update on BV partner treatment
- Concurrent Sexual Partner Therapy to Prevent Bacterial Vaginosis Recurrence in Obstetrics and Gynecology
This ACOG Clinical Practice Update reflects growing data on treating sexual partners of patients with bacterial vaginosis (BV). While partner therapy has been studied numerous times with mixed results, a more recent study from 2025 in the New England Journal of Medicine found significant improvement in outcomes when male partners were treated with both oral and topical agents. There is also evidence that BV behaves similarly to sexually transmitted infections based on both observational and microbiological data. Using the 2025 study’s eligibility criteria, ideal candidates for partner treatment are patients with symptomatic, recurrent BV infections who have a regular male sexual partner. However, providers can consider shared decision-making for patients with BV who do not meet these criteria, such as those in same-sex relationships, or those with recurrent but asymptomatic BV. More research is needed to clarify how best to extend partner treatment for BV to a broader cohort of people.
2. ACOG Committee Statement on Contraception Access
- Access to Contraception in Obstetrics and Gynecology
American College of Obstetricians and Gynecologists (ACOG) has updated its Committee Statement on Access to Contraception for the first time since 2015. The Statement underscores that access to contraception is fundamental to the health and well-being of pregnancy-capable individuals, even as evidence-based contraceptive care has come under increased attack since Dobbs in June 2022. ACOG highlights the importance of shared decision making, shifting the focus from the “most effective” methods to the best method for each individual patient. It also calls on reproductive healthcare providers to familiarize themselves with the history of coercion and institutionalized racism surrounding contraceptive care and to actively work to rebuild trust and reduce stigma among historically disenfranchised populations. The statement emphasizes the importance of being able to counsel on non-hormonal contraceptive methods in depth, as well as consider discontinuation of contraception to be integral to reproductive autonomy. Finally, both insurers and healthcare institutions should make all FDA-approved contraceptive options available, so that patients do not have to alter their selections due to copay or cost. This Committee Statement acknowledges the increasing need for advocacy and education in this area since the Dobbs decision and provides helpful references.
3. First trimester Rh immune globulin administration
- Provider Perspectives on De-Implementation of Routine Blood Typing and Rh Immune Globulin Administration in the First Trimester: A Qualitative Study in Women’s Health Issues
Historically, patients with Rh-negative blood types have received a dose of Rh immune globulin (Rh IG) for any vaginal bleeding in pregnancy to prevent sensitization and the formation of Rh antigens which can lead to the formation of dangerous antibodies in a future pregnancy. However, emerging research has shown that sensitization is extremely unlikely prior to 12 weeks gestational age, and forgoing Rh IG could reduce barriers to care, particularly for pregnant individuals seeking abortion. As practice recommendations evolve in response to updated science, it is helpful to understand healthcare professionals’ points of view. For this study, the authors interviewed obstetrician-gynecologists to better understand their perspectives on the de-implementation of Rh IG for first trimester bleeding. Study participants were generally aware of new evidence and embraced updated recommendations, but also described the difficulty of changing longstanding medical practice due to a variety of factors, including discrepancies between guidelines and institutional protocols. These insights can inform strategies to align clinical practice, institutional policies, and emerging evidence when de-implementing low-value or unnecessary interventions.
4. Abortion and EC knowledge among young people
To continue reading, become a member today.
Stay on top of policy updates, social media trends shaping your patients’ beliefs, and the latest clinical information and research – all in one place. Your membership helps sustain tools millions of young people rely on, including Bedsider.